NPHLA Tracker · GLP-1 & obesity drug pipeline (ClinicalTrials.gov)
GLP-1 & Obesity Drug Pipeline
Phase 2 and phase 3 clinical trials of GLP-1, amylin and other incretin-based obesity and metabolic medicines registered on ClinicalTrials.gov, with each study’s phase, recruitment status, sponsor and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 82
- Changed in 7 days
- 0
- Latest record
- Jurisdiction
- International / multiple
Records
82 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| TOPAZ: Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792Conditions: Acute Ischemic Stroke (AIS). Interventions: Tirzepatide; Standard Medical Care (SMC) | Not yet recruiting | Phase 2 / Phase 3 | yifang zhu | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07734792 (opens in a new tab)Primary source | System checked NPHLA updated |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis. Interventions: Survodutide; Placebo | Recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06632444 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872Conditions: Type 2 Diabetes Mellitus. Interventions: RO7795081; Semaglutide; Placebo | Active, not recruiting | Phase 2 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07112872 (opens in a new tab)Primary source | System checked NPHLA updated |
| SWIFT: Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial CancerNCT07820358Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endo…. Interventions: Semaglutide (Wegovy) weekly injection; LNG-IUD (Progestin); Structured Weight Loss Program | Not yet recruiting | Phase 2 | The Methodist Hospital Research Institute | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07820358 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-5: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06109311 (opens in a new tab)Primary source | System checked NPHLA updated |
| GATA-3: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)NCT05254314Conditions: Asthma. Interventions: Semaglutide Pen Injector 2.4mg weekly; Placebo | Active, not recruiting | Phase 2 | Vanderbilt University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05254314 (opens in a new tab)Primary source | System checked NPHLA updated |
| Elecoglipron: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusNCT07775404Conditions: Obesity; Overweight. Interventions: Elecoglipron; Placebo | Recruiting | Phase 3 | AstraZeneca | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07775404 (opens in a new tab)Primary source | System checked NPHLA updated |
| Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979Conditions: Obesity; Overweight. Interventions: ABBV-295; Placebo | Recruiting | Phase 2 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07752979 (opens in a new tab)Primary source | System checked NPHLA updated |
| REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174Conditions: Type 2 Diabetes. Interventions: Cagrilintide; Semaglutide; Placebo | Completed | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06323174 (opens in a new tab)Primary source | System checked NPHLA updated |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07817251 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667Conditions: Obesity. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07011667 (opens in a new tab)Primary source | System checked NPHLA updated |
| SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNCT07850050Conditions: Obesity. Interventions: Survodutide; Placebo | Not yet recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850050 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Conditions: Obesity; Type 2 Diabetes. Interventions: Cagrisema; Semaglutide | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07564414 (opens in a new tab)Primary source | System checked NPHLA updated |
| DEFINE: A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxinNCT03449251Conditions: Cardiovascular Diseases; Type 2 Diabetes Mellitus. Interventions: Apelin; Relaxin; Normal saline; Verapamil; LN Monomethyl arginine | Active, not recruiting | Phase 2 | Cambridge University Hospitals NHS Foundation Trust | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03449251 (opens in a new tab)Primary source | System checked NPHLA updated |
| ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. Interventions: Survodutide; Placebo matching survodutide | Not yet recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850063 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285Conditions: Overweight; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07253285 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864Conditions: Obesity. Interventions: survodutide; Placebo | Completed | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06077864 (opens in a new tab)Primary source | System checked NPHLA updated |
| REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796Conditions: Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05567796 (opens in a new tab)Primary source | System checked NPHLA updated |
| Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in ObesityNCT06771115Conditions: Obesity. Interventions: Placebo; VTX3232 30 mg; Placebo in combination with semaglutide; VTX3232 30 mg in combination with semaglutide | Completed | Phase 2 | Zomagen Biosciences Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06771115 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Interventions: ALN-PNP; Tirzepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07527910 (opens in a new tab)Primary source | System checked NPHLA updated |
| TOLEDDO: Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"NCT05305794Conditions: Double Diabetes. Interventions: Insulin + semaglutide treatment; Usual insulin treatment; Biological check-up | Recruiting | Phase 3 | Centre Hospitalier Universitaire Dijon | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05305794 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Interventions: Semaglutide; Tirzepatide; Berobenatide | Not yet recruiting | Phase 3 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07845500 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571Conditions: Obesity; Overweight. Interventions: LY3841136; Tirzepatide; Placebo | Completed | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06603571 (opens in a new tab)Primary source | System checked NPHLA updated |
| TIRZE-PAP: Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness TrialNCT07846865Conditions: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. Interventions: Continuous Positive Airway Pressure; Tirzepatide | Not yet recruiting | Phase 2 / Phase 3 | Woolcock Institute of Medical Research | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07846865 (opens in a new tab)Primary source | System checked NPHLA updated |
| SILENCED: Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide TreatmentNCT07171723Conditions: Obesity &Amp; Overweight. Interventions: Liver-Expressed Antimicrobial Peptide 2 (LEAP2); Placebo (saline) | Completed | Phase 1 / Phase 2 | University Hospital, Gentofte, Copenhagen | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07171723 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or ObesityNCT07724340Conditions: Adults With Overweight/Obesity and Type 2 Diabetes. Interventions: AT673 low dose; AT673 high dose; Placebo | Active, not recruiting | Phase 2 | Antag Therapeutics | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07724340 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808Conditions: Overweight or Obesity. Interventions: Olatorepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07685808 (opens in a new tab)Primary source | System checked NPHLA updated |
| SEMAFORCRANIO: SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 YearsNCT07845994Conditions: Craniopharyngioma, Child. Interventions: Semaglutide (Wegovy) weekly injection; Placebo weekly Injection | Not yet recruiting | Phase 3 | University Hospital, Angers | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07845994 (opens in a new tab)Primary source | System checked NPHLA updated |
| Tirzepatide for Obesity and Meth Use DisorderNCT06745128Conditions: Obesity; Methamphetamine Use Disorder. Interventions: Tirzepatide | Completed | Phase 2 | University of Texas Southwestern Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06745128 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722Conditions: Diabetes Mellitus, Type 2. Interventions: Retatrutide; Semaglutide | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06260722 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07794579 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)NCT03407079Conditions: Healthy Volunteers; Overweight. Interventions: Sucralose; Placebo | Recruiting | Phase 2 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03407079 (opens in a new tab)Primary source | System checked NPHLA updated |
| Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNCT07078838Conditions: Endometrial Cancer; Endometrial Intraepithelial Neoplasia; Grade 1 Endometrial Endometrioid Carcinoma. Interventions: Tirzepatide | Not yet recruiting | Phase 2 | UNC Lineberger Comprehensive Cancer Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07078838 (opens in a new tab)Primary source | System checked NPHLA updated |
| A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538Conditions: Obesity. Interventions: ARO-INHBE; Placebo; Tirzepatide | Recruiting | Phase 1 / Phase 2 | Arrowhead Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06700538 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)NCT07817875Conditions: Obesity. Interventions: Tirzepatide; Placebo | Not yet recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07817875 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-7: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093Conditions: Obesity; Overweight; Chronic Low Back Pain (CLBP). Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07035093 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Conditions: Diabetes Mellitus, Type 2. Interventions: Orforglipron; Dulaglutide | Not yet recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07668336 (opens in a new tab)Primary source | System checked NPHLA updated |
| COMMIT-CD: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099Conditions: Crohn's Disease; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06937099 (opens in a new tab)Primary source | System checked NPHLA updated |
| Tirzepatide for the Treatment of Cannabis Use DisorderNCT07265752Conditions: Cannabis Use Disorder. Interventions: Tirzepatide; Placebo | Not yet recruiting | Phase 2 | Brigham and Women's Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07265752 (opens in a new tab)Primary source | System checked NPHLA updated |
| COMMIT-UC: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086Conditions: Ulcerative Colitis; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06937086 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277Conditions: Obesity; Weight Gain. Interventions: Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06439277 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06383390 (opens in a new tab)Primary source | System checked NPHLA updated |
| ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06672549 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372Conditions: Chronic Kidney Disease; Type 2 Diabetes; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo | Completed | Phase 2 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06131372 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease. Interventions: Tirzepatide; Retatrutide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07165028 (opens in a new tab)Primary source | System checked NPHLA updated |
| RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884Conditions: Urinary Incontinence,Stress. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07202884 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593Conditions: Peripheral Arterial Disease. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07223593 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-RAM: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307Conditions: Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocr…. Interventions: Orforglipron | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07613307 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-OA PAIN: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471Conditions: Osteoarthritis. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07153471 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07241390 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) on the schedule set in the Source Registry: one broad search for obesity and incretin therapies (GLP-1, semaglutide, tirzepatide, retatrutide, orforglipron, amylin, cagrilintide, survodutide) and a separate search for each metabolic topic that has a trial query, such as retatrutide or orforglipron. Each study is stored with its registry fields exactly as published: title, phase, overall status, sponsor, conditions, interventions and the date of its last registry update.
When a study’s overall status changes, or results are first posted, the change is recorded with the date the pipeline detected it. This tracker lists studies on the Metabolic desk whose registered phase includes phase 2 or phase 3 (combined phase 2/3 studies included). Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch in phase 2 and phase 3 on the metabolic desk.
What does it cover?
Studies listed on ClinicalTrials.gov — from the United States and other countries — that match the search terms above, from the date tracking of each search began. Phase 2 and phase 3 only. Phase 1 and phase 4 studies, studies described with other terms and studies registered only in other registries are not included.
What are its limitations?
Registry records are maintained by trial sponsors and can lag events; the status shown is the sponsor’s registry status at the last check, not an assessment of the trial. Searches can include studies of these medicines for conditions other than obesity and can miss studies that use different terms. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry; the table reflects each completed check.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.